S&P 500   3,379.09 (-2.49%)
DOW   27,494.76 (-2.97%)
QQQ   277.45 (-2.56%)
AAPL   113.29 (-1.52%)
MSFT   208.77 (-3.45%)
FB   275.20 (-3.37%)
GOOGL   1,571.20 (-3.78%)
AMZN   3,162.66 (-1.30%)
TSLA   410.99 (-2.29%)
NVDA   522.08 (-3.96%)
BABA   303.85 (-1.96%)
CGC   18.52 (-6.13%)
GE   7.30 (-4.33%)
MU   51.43 (-2.69%)
AMD   81.21 (-0.92%)
T   27.19 (-2.26%)
F   7.95 (-2.57%)
ACB   4.39 (-6.20%)
GILD   59.69 (-1.81%)
NFLX   480.00 (-1.70%)
NIO   25.52 (-6.04%)
BA   159.78 (-4.53%)
DIS   123.23 (-3.99%)
S&P 500   3,379.09 (-2.49%)
DOW   27,494.76 (-2.97%)
QQQ   277.45 (-2.56%)
AAPL   113.29 (-1.52%)
MSFT   208.77 (-3.45%)
FB   275.20 (-3.37%)
GOOGL   1,571.20 (-3.78%)
AMZN   3,162.66 (-1.30%)
TSLA   410.99 (-2.29%)
NVDA   522.08 (-3.96%)
BABA   303.85 (-1.96%)
CGC   18.52 (-6.13%)
GE   7.30 (-4.33%)
MU   51.43 (-2.69%)
AMD   81.21 (-0.92%)
T   27.19 (-2.26%)
F   7.95 (-2.57%)
ACB   4.39 (-6.20%)
GILD   59.69 (-1.81%)
NFLX   480.00 (-1.70%)
NIO   25.52 (-6.04%)
BA   159.78 (-4.53%)
DIS   123.23 (-3.99%)
S&P 500   3,379.09 (-2.49%)
DOW   27,494.76 (-2.97%)
QQQ   277.45 (-2.56%)
AAPL   113.29 (-1.52%)
MSFT   208.77 (-3.45%)
FB   275.20 (-3.37%)
GOOGL   1,571.20 (-3.78%)
AMZN   3,162.66 (-1.30%)
TSLA   410.99 (-2.29%)
NVDA   522.08 (-3.96%)
BABA   303.85 (-1.96%)
CGC   18.52 (-6.13%)
GE   7.30 (-4.33%)
MU   51.43 (-2.69%)
AMD   81.21 (-0.92%)
T   27.19 (-2.26%)
F   7.95 (-2.57%)
ACB   4.39 (-6.20%)
GILD   59.69 (-1.81%)
NFLX   480.00 (-1.70%)
NIO   25.52 (-6.04%)
BA   159.78 (-4.53%)
DIS   123.23 (-3.99%)
S&P 500   3,379.09 (-2.49%)
DOW   27,494.76 (-2.97%)
QQQ   277.45 (-2.56%)
AAPL   113.29 (-1.52%)
MSFT   208.77 (-3.45%)
FB   275.20 (-3.37%)
GOOGL   1,571.20 (-3.78%)
AMZN   3,162.66 (-1.30%)
TSLA   410.99 (-2.29%)
NVDA   522.08 (-3.96%)
BABA   303.85 (-1.96%)
CGC   18.52 (-6.13%)
GE   7.30 (-4.33%)
MU   51.43 (-2.69%)
AMD   81.21 (-0.92%)
T   27.19 (-2.26%)
F   7.95 (-2.57%)
ACB   4.39 (-6.20%)
GILD   59.69 (-1.81%)
NFLX   480.00 (-1.70%)
NIO   25.52 (-6.04%)
BA   159.78 (-4.53%)
DIS   123.23 (-3.99%)
Log in
NYSE:APHA

Aphria Stock Forecast, Price & News

$4.54
-0.01 (-0.22 %)
(As of 10/26/2020 01:45 PM ET)
Add
Compare
Today's Range
$4.51
Now: $4.54
$4.65
50-Day Range
$4.22
MA: $4.75
$6.37
52-Week Range
$1.95
Now: $4.54
$6.44
Volume218,402 shs
Average Volume6.30 million shs
Market Capitalization$1.31 billion
P/E Ratio50.44
Dividend YieldN/A
Beta2.19
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone844 427 4742
Employees1,200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$179.29 million
Book Value$5.23 per share

Profitability

Net Income$-12,480,000.00

Miscellaneous

Market Cap$1.31 billion
Next Earnings DateN/A
OptionableNot Optionable
$4.54
-0.01 (-0.22 %)
(As of 10/26/2020 01:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APHA News and Ratings via Email

Sign-up to receive the latest news and ratings for APHA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aphria (NYSE:APHA) Frequently Asked Questions

How has Aphria's stock price been impacted by COVID-19?

Aphria's stock was trading at $2.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APHA stock has increased by 69.3% and is now trading at $4.57.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aphria?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aphria in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aphria
.

How were Aphria's earnings last quarter?

Aphria Inc. (NYSE:APHA) announced its earnings results on Thursday, October, 15th. The company reported ($0.02) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The firm had revenue of $145.70 million for the quarter, compared to analysts' expectations of $159.63 million. Aphria had a net margin of 5.75% and a negative return on equity of 0.30%. The business's revenue for the quarter was up 15.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.07 earnings per share.
View Aphria's earnings history
.

What price target have analysts set for APHA?

8 brokers have issued 1 year price targets for Aphria's shares. Their forecasts range from $7.00 to $11.75. On average, they expect Aphria's share price to reach $9.01 in the next twelve months. This suggests a possible upside of 97.1% from the stock's current price.
View analysts' price targets for Aphria
.

Are investors shorting Aphria?

Aphria saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 35,140,000 shares, a decrease of 10.3% from the August 31st total of 39,190,000 shares. Based on an average daily volume of 5,290,000 shares, the short-interest ratio is presently 6.6 days. Approximately 12.2% of the company's shares are sold short.
View Aphria's Short Interest
.

Who are some of Aphria's key competitors?

What other stocks do shareholders of Aphria own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), OrganiGram (OGI), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), KushCo (KSHB) and HEXO (HEXO).

Who are Aphria's key executives?

Aphria's management team includes the following people:
  • Mr. Irwin D. Simon, CEO & Chairman (Age 61)
  • Mr. Carl A. Merton, Chief Financial Officer
  • Dr. Christelle Gedeon L.L.B., Ph.D., Chief Legal Officer
  • Mr. Victor Neufeld, Special Advisor (Age 66)
  • Mr. Cole Cacciavillani, Special Advisor (Age 65)

What is Aphria's stock symbol?

Aphria trades on the New York Stock Exchange (NYSE) under the ticker symbol "APHA."

Who are Aphria's major shareholders?

Aphria's stock is owned by a number of retail and institutional investors. Top institutional investors include Actinver Wealth Management Inc. (0.05%) and TL Private Wealth (0.01%).

Which major investors are buying Aphria stock?

APHA stock was acquired by a variety of institutional investors in the last quarter, including TL Private Wealth, and Actinver Wealth Management Inc..

How do I buy shares of Aphria?

Shares of APHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aphria's stock price today?

One share of APHA stock can currently be purchased for approximately $4.57.

How big of a company is Aphria?

Aphria has a market capitalization of $1.32 billion and generates $179.29 million in revenue each year. The company earns $-12,480,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Aphria employs 1,200 workers across the globe.

What is Aphria's official website?

The official website for Aphria is aphriainc.com.

How can I contact Aphria?

Aphria's mailing address is 245 TALBOT STREET W., LEAMINGTON A6, N8H 1N8. The company can be reached via phone at 844 427 4742 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.